NCT03216226View on ClinicalTrials.gov

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

June 28, 2017

Primary Completion Date

February 13, 2018

Study Completion Date

February 13, 2018

Conditions
HypoglycemiaDiabetes Mellitus, Type 1
Interventions
DRUG

dasiglucagon

Glucagon Analog

DRUG

GlucaGen

Native Glucagon

Trial Locations (7)

32806

Compass Research, Orlando

83642

Advanced Clinical Research, Meridian

Unknown

CRC - Clinical Research Center, Medizinische Universität Graz, Graz

LMC Manna Research, Barrie

LMC Calgary, Calgary

LMC Diabetes & Manna Research, Toronto

Diabeteszentrum Hamburg West, Gemeinschaftspraxis für Innere Medizin, Hamburg

Sponsors

Lead Sponsor

Zealand Pharma

Collaborators (1)

SynteractHCR
All Listed Sponsors
collaborator

SynteractHCR

INDUSTRY

lead

Zealand Pharma

INDUSTRY

NCT03216226 - A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter